Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
New Microbes New Infect ; 4: 9-10, 2015 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-25830026

RESUMO

We report the case of a 37-year-old previously healthy woman diagnosed with a breast abscess due to Propionibacterium avidum after breast reduction surgery. This case emphasizes the potential pathogenicity and morbidity associated with this commensal skin organism.

2.
Br J Cancer ; 110(12): 2865-73, 2014 Jun 10.
Artigo em Inglês | MEDLINE | ID: mdl-24853185

RESUMO

BACKGROUND: Metastatic triple-negative breast cancer is mostly incurable, due to lack of suitable drug targets. The insulin-like growth factor (IGF) system could provide such a target, and IGF-1 receptor (IGF-1R)-directed agents are already available, but seem unable to control all the complexities of the system, including crosstalk with hypoxia-inducible pathways. METHODS: Migration of triple-negative MDA-231 breast cancer cells and its modulation by IGFs, the IGF-1R inhibitor NVP-AEW541 and the IGF-2-sequestering monoclonal antibody MAB292 were assessed by the scratch wound healing and Boyden chamber assays; the effect of topotecan (inhibiting hypoxia-inducible factor-1 (HIF-1)) under hypoxia was also evaluated. Constitutive as well as drug-modulated levels of components of the IGF and HIF-1 pathways were evaluated by western blotting and qPCR. RESULTS: IGF-induced migration of MDA-231 cells was not abrogated by the IGF-1R inhibitor NVP-AEW541, whereas IGF-2 sequestration by MAB292 significantly reduced cell migration. Under hypoxia, topotecan was also effective, likely by reducing HIF-1-induced IGF-2 release. Simultaneous targeting of IGF-1R and IGF-2 or HIF-1 completely abolished cell migration. CONCLUSIONS: IR activation may account for the failure of NVP-AEW541 to suppress MDA-231 cell migration. Ligand-targeting compounds, or co-inhibition of the IGF and HIF-1 systems, may prevent activation of compensatory signalling, thereby providing a valuable addition to IGF-1R inhibitor-based therapies.


Assuntos
Movimento Celular/efeitos dos fármacos , Subunidade alfa do Fator 1 Induzível por Hipóxia/antagonistas & inibidores , Fator de Crescimento Insulin-Like II/imunologia , Receptor IGF Tipo 1/antagonistas & inibidores , Neoplasias de Mama Triplo Negativas/tratamento farmacológico , Anticorpos Monoclonais/farmacologia , Hipóxia Celular/efeitos dos fármacos , Linhagem Celular Tumoral , Feminino , Humanos , Fator de Crescimento Insulin-Like I , Fator de Crescimento Insulin-Like II/antagonistas & inibidores , Células MCF-7 , Pirimidinas/farmacologia , Pirróis/farmacologia , Transdução de Sinais , Inibidores da Topoisomerase I/farmacologia , Topotecan/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...